Form 4: Cyclo Therapeutics CFO Acquires Stock Options
SEC Form 4 Filing
Joshua M. Fine, CFO of Cyclo Therapeutics, Inc., reports the acquisition of stock options.
Summary
- On June 3, 2024, Joshua M. Fine, the Chief Financial Officer of Cyclo Therapeutics, Inc., acquired 110,732 stock options with an exercise price of $1.28.
- The options vest over a one-year period in equal quarterly installments and expire on June 3, 2034.
- Following the transaction, Mr. Fine directly owns 110,732 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Form 4) regarding stock option acquisition by the CFO. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects.
Stakeholder Impact
- The acquisition of stock options by the CFO could be viewed positively by shareholders as it aligns management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of earliest transaction: Joshua M. Fine acquired stock options. |
| 06/03/2024 | Date the stock options were acquired. |
| 06/03/2034 | Expiration date of the stock options. |
| 06/05/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.